What new drugs or treatments can reduce the number of orthostatic hypotension episodes?

Pharmacological Treatments for Reducing Orthostatic Hypotension Episodes

For neurogenic orthostatic hypotension, midodrine and droxidopa are the primary FDA-approved medications that can reduce episodes, with midodrine showing dose-dependent improvement in standing blood pressure and symptoms, and droxidopa demonstrating efficacy in reducing falls in patients with Parkinson disease, pure autonomic failure, and multiple system atrophy. 1

First-Line Pharmacological Options

Midodrine

• Improves symptoms of OH with dose-dependent increases in standing blood pressure 1
• Primary limitation: supine hypertension
• Common side effects include scalp tingling, piloerection, and urinary retention
• Should be administered at lowest effective dose and frequency that improves symptoms 2

Droxidopa

• Specifically beneficial for neurogenic OH due to Parkinson disease, pure autonomic failure, and multiple system atrophy 1
• May reduce falls according to small studies
• Important caveat: carbidopa in Parkinson's patients may decrease droxidopa effectiveness
• Limited by supine hypertension, headache, dizziness, and nausea

Second-Line Pharmacological Options

Fludrocortisone

• Increases plasma volume, resulting in symptom improvement 1
• Should be used AFTER other medications when supine hypertension is present 1
• Doses >0.3 mg daily risk serious adverse reactions including adrenal suppression and immunosuppression
• Common side effects: edema, hypokalemia, headache

Pyridostigmine

• Reserved for patients refractory to other treatments 1
• Works by facilitating cholinergic neurotransmission in autonomic ganglia 2
• Improves orthostatic tolerance through increased peripheral vascular resistance
• Side effects: nausea, vomiting, abdominal cramping, sweating, salivation, urinary incontinence

Emerging and Specialized Therapies

Atomoxetine

• Emerging evidence shows promise, especially in central autonomic failure 3
• Blocks norepinephrine reuptake in nerve terminals 2
• May prove viable alternative treatment option, though more data needed

Octreotide

• Reserved for refractory recurrent postprandial or neurogenic OH 1
• Reduces splanchnic blood flow by ~20%, preventing postprandial hypotension
• Increases blood pressure and improves orthostatic tolerance

Ivabradine

• Suggested for POTS patients (2.5-7.5 mg twice daily) 4
• Alternative to β-blockers when prominent symptomatic orthostatic tachycardia present
• Caveat: may be teratogenic; adequate contraception required in women of childbearing potential
• Limited availability in Canada due to off-label use

Critical Treatment Algorithm

Step 1: Start with midodrine or droxidopa as first-line agents based on etiology

• Choose midodrine for general neurogenic OH
• Choose droxidopa specifically for Parkinson disease, pure autonomic failure, or multiple system atrophy

Step 2: If supine hypertension develops, avoid fludrocortisone and consider pyridostigmine or atomoxetine instead

Step 3: For refractory cases, add pyridostigmine or consider octreotide for postprandial component

Step 4: Monitor for supine hypertension with all pressor agents; this is the primary limiting factor for dose escalation

Important Caveats

• Treatment goal is symptom relief and fall prevention, NOT arbitrary blood pressure targets 5
• All pressor agents risk worsening supine hypertension, which complicates management 6, 5
• Medication review to discontinue offending agents (diuretics, vasodilators, tamsulosin, tizanidine, sildenafil, trazodone, carvedilol) is essential before adding new medications 2
• The field is moving toward treating OH and supine hypertension as a coupled disorder requiring mechanism-based treatment selection 6